June 1, 2009
Recorded March 31, 2009 in Orlando
Robert M Califf MD
Professor of Medicine
Donald F Fortin Professor, Cardiology
Vice Chancellor for Clinical Research
Director, Duke Translational
Medicine Institute
Duke University Medical Center
Durham, NC
To view Dr Califf's conflict of interest statement, click here
Steve E Nissen MD
Chair, Department of Cardiovascular Medicine
Heart and Vascular Institute Cleveland Clinic
Professor of Medicine
Cleveland Clinic Lerner College of Medicine
Case Western Reserve University
Cleveland, Ohio
Past President, American College of Cardiology
Washington, DC
Dr Nissen reports that he has received research support to perform clinical trials through the Cleveland Clinic Coordinating Center for Clinical Research from Pfizer, AstraZeneca, Novartis, Roche, Daiichi-Sankyo, Takeda, Sanofi-Aventis, Resverlogix, and Eli Lilly. Dr Nissen consults for many pharmaceutical companies, but requires them to donate all honoraria or consulting fees directly to charity so that he receives neither income nor a tax deduction.
Recorded March 31, 2009 in Orlando
Professor of Medicine
Donald F Fortin Professor, Cardiology
Vice Chancellor for Clinical Research
Director, Duke Translational
Medicine Institute
Duke University Medical Center
Durham, NC
To view Dr Califf's conflict of interest statement, click here
Chair, Department of Cardiovascular Medicine
Heart and Vascular Institute Cleveland Clinic
Professor of Medicine
Cleveland Clinic Lerner College of Medicine
Case Western Reserve University
Cleveland, Ohio
Past President, American College of Cardiology
Washington, DC
Dr Nissen reports that he has received research support to perform clinical trials through the Cleveland Clinic Coordinating Center for Clinical Research from Pfizer, AstraZeneca, Novartis, Roche, Daiichi-Sankyo, Takeda, Sanofi-Aventis, Resverlogix, and Eli Lilly. Dr Nissen consults for many pharmaceutical companies, but requires them to donate all honoraria or consulting fees directly to charity so that he receives neither income nor a tax deduction.
Dr Robert Califf conducts a series of in-depth and personal interviews with his peers in the world of cardiology to find out what makes them tick, how they feel about the future, and what the lessons they have learned during their exceptional careers.
In Episode One of the series, join Dr Califf as he talks to Dr Steven Nissen about how he became one of the world's leading cardiologists and a "rebel with a cause," from his secret childhood forays into Disneyland, through his protest years at the University of Michigan, to his current involvement in national healthcare reform.
This program is part of an editorial series that consists of independent, unsupported programs developed by theheart.org.
This program is part of an editorial series that consists of independent, unsupported programs developed by theheart.org.
Related links:
-
CAPTIVATE published: Trial stopped early, and pactimibe development discontinued based on IVUS results.
[Clinical Conditions > Lipid/Metabolic > Lipid/Metabolic]; Mar 17, 2009.
Red flags raised over FDA advisory-panel hearing on prasugrel
[Clinical Conditions > Acute Coronary Syndromes > Acute coronary syndromes]; Feb 13, 2009.
Nissen to Obama: How to heal the ailing FDA
[HeartWire > Murmurs]; Jan 20, 2009.
WSJ report highlights GlaxoSmithKline concerns with rosiglitazone
[HeartWire > MediaPulse]; Jan 14, 2009
Older patients face higher mortality, CHF hospitalizations with rosiglitazone over pioglitazone
[Clinical Conditions > Heart failure > Heart failure]; Nov 24, 2008.
Rosiglitazone US labeling updated to include ADOPT findings
[Clinical Conditions > Lipid/Metabolic > Lipid/Metabolic]; Jul 14, 2008.
Episode #6: Dr Steve Nissen: Is fellows' training too long?
The Fellows' corner on theheart.org
